Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data

被引:161
作者
Lombardo, F [1 ]
Obach, RS
Shalaeva, MY
Gao, F
机构
[1] Pifzer Global Res & Dev, Groton Labs, Mol Properties Grp, Pharmacokinet Dynam & Metab, Groton, CT 06340 USA
[2] Pifzer Global Res & Dev, Groton Labs, Nonclin Stat Grp, Groton, CT 06340 USA
关键词
D O I
10.1021/jm0200409
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We present a method for the prediction of volume of distribution in humans, for neutral and basic compounds. It is-based on two experimentally determined physicochemical. parameters, ElogD(7.4) and fi((7.4)), the latter being the fraction of compound ionized at pH 7.4 and on the fraction of free drug in plasma (f(u)). The fraction unbound in tissues (f(ut)), determined via a regression analysis from 64 compounds using the parameters, described, is then used to predict VDss via the Ole-Tozer equation. Accuracy of this method was determined using a test set of 14 compounds, and it was demonstrated that human VDss values could be predicted, on average, within or very close to 2-fold of the actual value. The present method is as accurate as reported methods based on animal pharmacokinetic data, using a similar set of compounds, and ranges between 1.62 and 2.20 as mean-fold error. This method has the advantage of being amenable to automation, and therefore fast throughput, it is compound and resources sparing, and it offers a rationale for the reduction of the use of animals in pharmacokinetic studies. A discussion of the potential errors that may be encountered, including errors in the determination of f(u), is offered, and the caveats about the use of computed vs experimentally determined logD and pK(a) values are addressed.
引用
收藏
页码:2867 / 2876
页数:10
相关论文
共 100 条
[1]  
ALESSISEVERINI S, 1992, ANAL PROFILES DRUG S, V21, P169
[2]   Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs [J].
Allen, RI ;
Box, KJ ;
Comer, JEA ;
Peake, C ;
Tam, KY .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (4-5) :699-712
[3]   CLINICAL PHARMACOKINETICS OF CHLORAMPHENICOL AND CHLORAMPHENICOL SUCCINATE [J].
AMBROSE, PJ .
CLINICAL PHARMACOKINETICS, 1984, 9 (03) :222-238
[4]  
ANDREASEN PB, 1974, CLIN PHARMACOL THER, V16, P1059
[5]  
[Anonymous], ANAL PROFILES DRUG S
[6]  
BANKER MJ, 2001, Patent No. 1088589
[7]  
BARBATO F, 1990, FARMACO, V45, P647
[8]   NICOTINE AND COTININE ELIMINATION PHARMACOKINETICS IN SMOKERS AND NONSMOKERS [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (03) :316-323
[9]  
BERGSTROM L, 1989, BR J CLIN PHARM, V27, P49
[10]  
Bickel M.H., 1994, ADV DRUG RES, V25, P55